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Background: The role of transforming growth factor-b (TGF-b) in the development of hepatic metastasis
from colon cancer is not clearly elucidated. The aim of this study was to determine the role of TGF-b in
the development of such metastasis.
Methods: Two human colon cancer cell lines were utilized: FET-a cells (intact TGF-b inhibitory response),
and CBS cells (defects in TGF-b inhibitory response caused by a deficiency in type II receptor activity).
The ability of these cell lines to metastasize was analysed in an orthotopic colon cancer mouse model.
Results: FET-a cells did not metastasize to the liver, but showed lung metastasis in 10% of the animals,
whereas CBS cells gave rise to metastasis in 65%. Following the elimination of TGF-b activity by
transfection and overexpression of dominant negative type II receptor, FET-a cells demonstrated liver and
lung metastasis in 70% of the animals. Similarly, after the restoration of type II receptor activity by ectopic
expression, CBS cells formed metastasis in fewer (10%) animals.
Conclusions: The results of our study demonstrate for the first time that TGF-b displays selective
metastasis suppressor activity. These abnormal pathways can serve as selective targets for future
development of targeted therapies.
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Introduction
Successful metastatic colonization involves several processes.
These include invasion at the primary site, intravasation into the
circulation, escape from immune surveillance, extravasation into
a distal organ and establishment of metastatic colonies at this
secondary organ site. The molecular mechanisms involved in the
individual steps of the process are not well characterized.1 The
development of aberrant cell survival signalling is required for
each step of the process and there is evidence that different
molecular mechanisms for aberrant survival signalling can occur
at each step.2 The determination of these survival mechanisms
could potentially provide a basis for the development of thera-
peutic interventions to address the high death rates associated
with metastatic disease in major cancers. Aberrant cell survival
mechanisms arise in response to stress.3 Evasion of apoptosis can
occur as a result of loss of tumour suppressor activity or
enhanced oncogenic activity, which shifts the balance of stress
response toward resistance to cell death.
The transforming growth factor-b (TGF-b) signalling pathway
is involved in the control of several biologic processes, including
cell proliferation, differentiation, migration and apoptosis, and is
one of the most commonly altered pathways in human cancers.4
The TGF-b ligand family consists of three members: TGF-b1,
TGF-b2 and TGF-b3. TGF-b signalling is transduced by the serine/
threonine type I TGF-b receptor (TGF-b RI) and type II
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TGF-b receptor (TGF-b RII) found in most cell types. TGF-b
ligand stimulation results in activation of TGF-b RII serine/
threonine kinase activity followed by receptor heteromerization
with TGF-b RI and the activation of this component by trans-
phosphorylation. Activated TGF-b RI receptor serine/threonine
kinase then transmits signals through phosphorylation of
receptor-activated Smads (R-Smads) to regulate transcription of
target genes as well as Smads transcription-independent signalling
mechanisms.5
The general consensus is that TGF-b is a multi-functional
cytokine that plays a dichotomous role in tumour progression.6–10
TGF-b signalling is tumour-suppressive in early carcinogenesis,
but becomes tumour-promoting during later stages of cancer,
which leads to the development of metastasis. TGF-b signalling
through Smad activation is regarded as tumour-suppressive
during the early stages of cancer and pre-cancerous lesions as it
has been shown that loss of TGF-b tumour suppressor signalling,
at either the ligand or receptor level, has been associated with
tumour initiation and the progression of several types of tumours,
including colon cancer. Epigenetic transcriptional repression and
DNA methylation of TGF-b RI or TGF-b RII has been observed in
a variety of tumour types,11,12 and TGF-b RII is inactivated by
mutation in human colon cancers with microsatellite instability.13
By contrast, it has been reported that increased TGF-b1 expres-
sion by tumour cells correlated with tumour progression in non-
small cell lung cancer (NSCLC), colorectal cancer and gastric
carcinomas.14–16 Similarly, other authors have demonstrated the
tumour progression and metastasis-enhancing potential of
TGF-b.17–19 TGF-b signalling has also been shown to prime breast
tumour cells for metastasis by promoting their extravasation from
blood vessels to distal organ sites.20
Therefore, the exact roles of the pleiotropic TGF-b functions in
the development of metastasis in colorectal cancer are not clear. A
direct association of TGF-b signalling with the initiation of colon
cancer metastasis has not yet been identified. The aim of our study
was to investigate the role of TGF-b in the development of hepatic
metastasis from colorectal cancer in an orthotopic mouse model.
Materials and methods
Cell lines and reagents
The FET colon cancer cell line does not normally form tumours in
athymic mice,21 but becomes highly tumorigenic after transfection
(FET-a) with transforming growth factor-a (TGF-a).22 FET-a
cells are highly tumorigenic, exhibit growth factor independence
and are highly invasive (100%) at the orthotopic primary site in
vivo, but do not metastasize.23 It has been shown that FET cells
have robust autocrine TGF-b signalling that inhibits cell prolif-
eration and contributes to apoptosis in response to stress such as
growth factor deprivation stress (GFDS).3 Although FET-a cells
have an aberrant oncogenic pathway constitutive (TGF-a/
epidermal growth factor receptor [EGFR]) signalling, they retain
an intact TGF-b tumour suppressor signalling pathway which
prevents them from forming metastasis.
FET-a-DN cells were developed by repressing TGF-b activity
by transfection with a dominant negative (DN) receptor II con-
struct. Repression of TGF-b activity has been shown to lead to
vigorous progressive expansion of subcutaneous implants.24 The
CBS colon cancer cell line is also highly invasive (100%) at the
orthotopic primary site, but is associated with a high metastatic
potential ranging up to 65%.
FET-a and FET-a-DN colon carcinoma cells were cultured at
37 °C in a humidified atmosphere of 5% CO2 in SM medium
(McCoy’s 5A serum-free medium [Sigma-Aldrich, Inc., St Louis,
MO, USA] with pyruvate, vitamins, amino acids and antibiotics)
supplemented with 10 ng/ml epidermal growth factor, 20 mg/ml
insulin, and 4 mg/ml transferrin. Antibodies for Akt and phospho-
rylated Akt (Ser473) were obtained from Cell Signaling Technol-
ogy (Danvers, MA, USA). Actin and tubulin antibodies were
purchased from Sigma-Aldrich, Inc. pSmad2 antibodies were
obtained from the Chemicon Division of Millipore Corp.
(Bedford, MA, USA) and Abcam, Inc. (Cambridge, MA, USA),
respectively. PI3K inhibitor LY294002, and TGF-b were obtained
from the Calbiochem Division of EMD Chemicals, Inc. (Gibb-
stown, NJ, USA). ApopTag Plus Peroxidase In Situ Apoptosis
Detection Kit was sourced from the Chemicon Division of Milli-
pore Corp. and both the Dako Envision System HRP and the
monoclonal anti-human KI-67 antigen (Clone Mib-1) were
obtained from Dako Corp. (Carpinteria, CA, USA). An Annexin
V-FITC Apoptosis Detection Kit (including propidium iodide)
was sourced from BD Biosciences Pharmingen (San Jose, CA,
USA) and a Cell Death Detection ELISAPLUS Kit was sourced from
Roche Diagnostics, Inc. (Indianapolis, IN, USA). Haematoxylin
was obtained from Protocol and eosin was purchased from Sigma-
Aldrich, Inc.
Ectopic expression of dominant negative
TGF-b RII receptor
The DN RII expression vector has been described previously.24
The truncated TGF-b RII encoded amino acid residues 1–283 of
the human RII; thus, most of the serine/threonine kinase domain
and COOH-terminal tail of the normal human RII is absent from
DN RII protein. The truncated cDNA was subcloned into an
MX-IV retroviral vector. The 293GP packaging cells (Clontech
Laboratories, Inc., Mountain View, CA, USA) were co-transfected
with the truncated construct and pVSV-G. The viruses were
harvested 48 h later and used to infect FET-a cells. Puromycin
(3.0 mg/ml) was used to select infected cells for 8 days, after which
cells were pooled.
Immunoblot analysis
Cells were lysed in TNESV lysis buffer (50 mmol/l Tris [pH 7.5],
150 mmol/l NaCl, 1% NP40, 50 mmol/l NaF, 1 mmol/l Na3VO4,
25 mg/ml h-glycerophosphate, 1 mmol/l phenylmethylsulfonyl
fluoride, one protease inhibitor cocktail tablet [Roche Diagnos-
tics, Inc.] per 10 ml) for 30 min on ice. The supernatants were
then collected by centrifugation for 15 min. Protein was deter-
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mined by the Pierce BSA (bovine serum albumin) method.
Protein samples were dissolved in 1¥ sample buffer (50 mM Tris
[pH 6.8], 1% SDS, 10% glycerol, 0.03% bromophenol blue and
1% b-mercaptoethanol). Protein (10–50 mg) was fractionated on a
10% acrylamide denaturing gel and transferred onto a nitrocellu-
lose membrane (Amersham Life Science, Inc., Arlington Heights,
IL, USA) by electroblotting. The membrane was blocked with 5%
non-fat dry milk in TBST (50 mmol/l Tris [pH 7.5], 150 mmol/l
NaCl, 0.05% Tween 20) for 1 h at room temperature or overnight
at 4 °C and washed in TBST. The membrane was then incubated
with primary antibodies at 1 : 1000 dilutions for 1 h at room
temperature or overnight at 4 °C. The membranes were washed
with TBST for 30 min and then incubated with peroxidase-
conjugated goat anti-mouse or anti-rabbit IgG (Jackson Immu-
noResearch Laboratories, Inc., West Grove, PA, USA) at a 1 : 1000
dilution for 1 h at room temperature and washed again in TBST
for 30 min. Proteins were then detected by the enhanced chemi-
luminescence (ECL) system (Amersham Life Science, Inc.).
MTT assay
Cells were grown to 80% confluence, after which MTT (3-[4,
5-dimethylthiazoll-2-yl]-2, 5-diphenyltetrazolium bromide) was
added to the medium, which was then incubated at 37 °C for 2 h.
The medium was aspirated to visualize stained cells. Dimethyl
sulphoxide (DMSO) was added and the plate was covered with foil
and shaken for 15 min. Duplicate volumes (150 ml) were added to
a 96-well plate and absorbance was observed at 570 nm.
TGF-b growth inhibition assay
[3H]Thymidine incorporation was used to determine growth
inhibition of FET-a and FET-a-DN cells after TGF-b treatment.
The cells were seeded in six-well tissue culture plates and grown to
60% confluence. At 48 h after TGF-b treatment, the cells were
labelled with [3H]thymidine (7 mCi; 46 Ci/mmol [Amersham
Corp.]) for 1 h. DNA was then precipitated with 10% trichloro-
acetic acid and solubilized in 0.2 mol/l NaOH. The amount of
[3H]thymidine incorporated was analysed by liquid scintillation
counting in a Beckman LS7500 scintillation counter.
Annexin V-PI staining
An Annexin V-FITC Apoptotic Kit (BD Biosciences Pharmingen)
was used to assess apoptosis. Cells were grown to 80% confluence
and harvested or growth factor-deprived for 24 h or 48 h. Cells
were washed with phosphate-buffered saline (PBS) and then
re-suspended in binding buffer (10 mmol/l Hepes/NaOH [pH
7.4], 140 mmol/l NaCl, 2.5 mmol/l CaCl2) to a cell density of
1 ¥ 106 cells/ml. Cell suspensions (100 ml: 106 cells) were stained
with annexin V-FITC and propidium iodide (PI) at room tem-
perature for at least 15 min in the dark. Cells were analysed in an
FACS Calibur flow cytometer within 1 h of staining. The data were
analysed with CellQuest Pro (BD Biosciences, Inc., San Jose,
CA, USA).
Immunohistochemistry
Primary tumours established from the FET-a and FET-a-DN
cells were harvested and placed in 10% neutral buffered formalin
fixative for 12–24 h and then embedded in paraffin. Deparaf-
finized tissue specimens were subjected to immunohistochemical
staining for the detection of pAkt-S473 using an indirect detection
method according to Sharkey et al.25 The catalysed signal ampli-
fication system was used for the phosphospecific antibodies (Dako
Corp.). Antibody staining was accompanied by a negative control
in which slides were incubated with a matching blocking peptide
(obtained from same company as the primary antibody) to the
primary antibody. Specimens were processed on the same day
to eliminate any variability in conditions. Slides were digitally
photographed using the same settings.
TUNEL assay
Slides were cut from paraffin-embedded blocks and stained
according to the ApopTag TUNEL (terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labelling) Assay Kit (Oncor,
Inc., Gaithersburg, MD, USA). The apoptotic rate was quantita-
tively determined by counting the number of positively stained
apoptotic bodies per 75-mm2 field at magnification ¥20. Twelve
and 15 histological slides for the FET-a and FET-a-DN tumours,
respectively, were analysed. Three histologically similar fields
viewed at magnification ¥20 were randomly selected from each
slide for analysis. This procedure was performed by two blinded
observers. The ratio of the average number of apoptotic cells to
the total number of cells counted was used to represent apoptotic
rates.
KI-67 staining
Haematoxylin and eosin (H&E) staining was performed on tissue
blocks used for immunohistochemical characterizations. Serial
sections were cut to complement the H&E sections and were
stained with an IgG1 rabbit polyclonal antibody for KI-67 (Dako
Corp.). KI-67 is a non-histone nuclear antigen present in late G1,
G2 and S phases of the cell cycle, but not in G0. The optimal
dilution of 1 : 100 was used. Sections of 3–4 mm were cut, depar-
affinized in xylene, and rehydrated in descending grades of
ethanol. Endogenous peroxidase activity was blocked with 3%
hydrogen peroxide in water. Immunostaining was carried out
using a variation of the avidin-biotin-peroxidase method. Slides
were counterstained with methyl green. The proliferation rate was
determined quantitatively using NIH Image J (public domain
software). Image settings used a threshold range of 10–192 and a
pixel size of 20–5000. Twelve slides from FET-a and FET-a-DN
were analysed. Three histologically similar fields viewed at mag-
nification ¥20 were randomly selected for analysis. The mean
proliferation was determined for each group.
Orthotopic implantation
Orthotopic implantation was performed as previously described.25
Briefly, green fluorescent protein (GFP)-labelled FET-a and FET-
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a-DN cells were subcutaneously injected onto the dorsal surfaces
of separate BALB/c nude male mice and allowed to grow to
300 mm3. When the xenografts were established, they were excised
and minced into 1-mm3 pieces. Two of these pieces were then
orthotopically implanted into other BALB/c nude mice. Forty-four
animals were implanted with FET-a cells and 30 animals with
FET-a-DN cells. For operative procedures, animals were anaesthe-
tized with isoflurane inhalation. A 1-cm laparotomy was per-
formed and the cecum and ascending colon were exteriorized.
Using magnification ¥7 and microsurgical techniques, the serosa
was disrupted in two locations. Pieces of xenograft (1 mm3) were
subserosally implanted using an 8–0 nylon suture at the disrupted
serosal locations. The bowel was then returned to the peritoneal
cavity and the abdomen was closed with a 5–0 vicryl suture.
Fluorescence imaging was carried out weekly on the animals to
follow tumour growth and progression (Lightools Research,
Encinitas, CA, USA). The animals were killed at days 50 (mice
implanted with FET-a) and 63 (mice implanted with FET-a-DN)
after implantation. Organs were explanted, imaged and immedi-
ately placed in buffered 10% formalin. Tissues were then processed
and embedded in paraffin. Slides were cut for H&E staining.
Results
TGF-b suppresses metastasis in vivo
Our laboratory has shown that constitutive activation of EGFR by
ectopic expression of TGF-a results in tumour formation in both
xenograft and orthotopic implantation in in vivo models of the
FET colon carcinoma cell line.25 Orthotopic implantation of
FET-a generates invasion at the primary tumour site. These cells
retain a robust inhibitory response to TGF-b, suggesting that
TGF-b tumour suppressor signalling does not suppress tumour
initiation or progression to malignancy in this model (as reflected
by the acquisition of an invasive capability). As the FET-a cells do
not readily metastasize, we hypothesized that TGF-b signalling
was acting as a suppressor of metastasis. To test this hypothesis, we
stably co-transfected FET-a cells with a truncated kinase domain
DN RII receptor construct (nucleotides 1–283) and pVSV-G, and
denoted these cells as FET-a-DN. Stably transfected cell pools
were obtained by puromycin selection and compared with pooled
FET-a cells. Abrogation of TGF-b signalling was confirmed by
growing FET-a and FET-a-DN cells to 70% confluence and then
treating the cells with varying concentrations of TGF-b (0 ng/ml,
5 ng/ml, 10 ng/ml) for 2 h followed by immunoblotting analysis.
pSmad2 was used as an indicator of functional TGF-b inhibitory
signalling. FET-a cells showed a concentration-dependent induc-
tion of pSmad2, whereas FET-a-DN cells showed no pSmad2
expression. This result confirmed the loss of TGF-b sensitivity in
FET-a-DN (Fig. 1). Further characterization for loss of TGF-b
inhibitory activity in FET-a-DN cells was performed using a
growth inhibitory assay. Briefly, cells were grown to 60% conflu-
ence and then treated with TGF-b for 48 h, after which they were
labelled with [3H]thymidine for 1 h and DNA precipitation. The
amount of [3H]thymidine incorporated was analysed by liquid
scintillation counting. Changes in growth were assessed by nor-
malizing results to FET-a in the absence of exogenous TGF-b. The
results (Fig. 2) showed that FET-a cells exhibited a 60% decrease
in tritiated thymidine incorporation into newly synthesized DNA,
whereas no change was observed in FET-a-DN cells in the absence
or presence of exogenous TGF-b. Thus, the growth inhibitory
effects of TGF-b, as well as TGF-b receptor-mediated Smad sig-
nalling, were eliminated from FET-a cells by transfection of the
DN RII construct, as expected.
The comparison of FET-a and FET-a-DN cells by orthotopic
implantation was used to assess the effect of loss of TGF-b inhibi-
tory signalling on malignant progression and metastasis. Expo-
nentially growing GFP-labelled FET-a and FET-a-DN cells
(5 ¥ 106) were subcutaneously inoculated into athymic nude
mice and allowed to grow to 300 mm3 as determined by two-
dimensional calliper measurements. When the xenografts were
established, they were excised and minced into 1-mm3 pieces.
Pairs of these pieces were then implanted onto the colons of other
BALB/c nude mice. A total of 44 animals were implanted with
TGF-β(ng/ml)2h
p-Smad2
Actin
FET-α FET-α-DN
0 5 10 0 5 10
Figure 1 TGF-b sensitivity abrogated in FET-a-DN cells. FET-a and
FET-a-DN cells were grown to 70% confluence and then treated with
0 ng/ml, 5 ng/ml or 10 ng/ml TGF-b for 2 h. Cells were harvested
and immunoblot analysis was performed with pSmad2 and Smad2
antibodies. Actin was used as a loading control
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Figure 2 TGF-b signalling renders a growth inhibitory effect on
FET-a cells. FET-a and FET-a-DN cells were grown to 60% conflu-
ence and then treated with 5 ng/ml TGF-b for 48 h. Cells were
labelled with [3H]thymidine for 1 h followed by DNA precipitation and
solubilization. The amount of [3H]thymidine was analysed
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FET-a cells and 30 animals were implanted with FET-a-DN cells.
Weekly fluorescence imaging with GFP was used as a gross means
of following tumour growth and progression. Figure 3 shows GFP
imaging of primary colon carcinoma during xenografting and
orthotopic implantation (open and closed abdomen). The lungs
and liver were excised, imaged and immediately placed in buffered
10% formalin. Imaging with GFP also facilitated the identification
of metastatic disease. Metastatic colony formation was seen in
lung tissue from FET-a-DN orthotopically implanted animals,
but not in lung tissue from FET-a orthotopically implanted
animals. There was 100% primary tumour growth at the site of
implantation in all animals, indicating that the FET-a-DN cells,
like FET-a cells, were fully invasive. Invasion at the primary
tumour site and metastatic colonization were evaluated by H&E
staining, which confirmed that FET-a and FET-a-DN cells were
highly invasive. A significant difference was observed in the meta-
static potential between the two FET transfected cell lines. The
group of animals with FET-a implants showed a 5% metastatic
rate (two of 44 animals with orthotopic implants) as assessed by
H&E staining of five histological slides bread-loafed from each
lung and each lobe of the liver. This can be compared with the
77% metastatic rate (23 of 30 animals) observed in animals with
FET-a-DN implants. The presence of metastatic colonies in
animals with FET-a-DN implants suggests that these cells may
have acquired enhanced survival capabilities that enable them to
extravasate and form new colonies at a distal organ site as a result
of loss of TGF-b inhibitory signalling.
Proliferation and survival were assessed by KI-67 immuno-
histochemistry and TUNEL assays, respectively. KI-67 is
a non-histone nuclear antigen present in late G1, S, G2, and M
phases of the cell cycle, but not in G0.26,27 It is used as an indi-
cator of cells undergoing proliferation. The TUNEL assay is
used to assess DNA fragmentation, an indicator of apoptosis, by
using the terminal nucleotidyl transferase (TDT) enzyme to
catalyse the addition of dUTPs that are secondarily labelled
with a marker that allows visualization.26 Immunohistochemical
staining of KI-67 showed that both FET-a and FET-a-DN
cells had positive staining for KI-67 antigen. KI-67 staining
indicated no difference in proliferation rates between
animals with FET-a implants and those with FET-a-DN
implants. However, TUNEL staining was ~2.5-fold higher in
tumours from mice with FET-a implants than in those
from mice with FET-a-DN, which indicates a significantly
higher rate of cells undergoing apoptosis in FET-a tumours.
Taken together, these results indicate that TGF-b signalling in
this colon carcinoma cell line is not capable of suppressing
tumour initiation or invasion at the primary site, but is
capable of suppressing the progression of an invasive carcinoma
with 100% penetrance from evolving to a robust metastatic
capability. Thus, shifting the tumour suppressor/oncogenic
balance toward oncogenesis by constitutive EGFR activation
allows for malignancy, but not a fully metastatic phenotype
because of continued metastasis suppressor signalling by
TGF-b.
Figure 3 Green fluorescent protein imaging. (A) Xenografting in subcutaneous location followed by harvesting the tumour and mincing to
pieces. (B) Imaging of tumour within the abdomen
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Abrogation of TGF-b tumour suppressor signalling
in vitro results in enhanced survival during GFDS
The ability of FET-a cells to invade the primary site, but not to
carry out subsequent aspects of the metastatic cascade as a result
of TGF-b signalling suggests that this tumour suppressor activity
is strong enough to shift the balance of tumour suppressor/
oncogenesis toward cell death when these cells encounter the
stresses associated with circulation and/or colonization in the
foreign microenvironment of distant organs. However, the loss of
the tumour suppressor activity associated with TGF-b would be
expected to shift this balance toward a higher capacity for cell
survival in FET-a-DN cells. To test the hypothesis that the loss of
TGF-b tumour suppressor signalling results in a higher capacity
for cell survival, we utilized growth factor deprivation as a cell
survival stress model to compare FET-a and FET-a-DN cells.
Apoptosis, or programmed cell death, is associated with a set of
morphological characteristics which include translocation of
membrane phospholipids, caspase activation, plasma membrane
blebbing, cell shrinkage, chromatin condensation and fragmenta-
tion.27 Cells were deprived of growth factors for 48 h, after which
assays directed at different characteristics of apoptosis were per-
formed. We utilized annexin V conjugated to FITC to ascertain cell
membrane integrity (the loss of which is an indicator of apopto-
sis). An early indicator of apoptosis is the translocation of the
membrane phospholipid phosphatidylserine from the inner to the
outer leaflet of the plasma membrane.28 Once phosphatidylserine
is exposed to the extracellular environment it can be bound by
annexin V (a phospholipid binding protein) conjugated to FITC,
allowing fluorescence visualization and quantification of positive
cells. Annexin V-FITC was used in combination with PI to distin-
guish cells that were in early apoptosis from cells that had lost
membrane integrity completely (indicated by PI staining of
DNA).29 Figure 4A shows the results of annexin V-FITC/PI stain-
ing of FET-a and FET-a-DN cells that were grown to 80% con-
fluence and then subjected to GFDS for 48 h. The upper left
quadrant shows cells that stained positive for PI (indicative of cells
undergoing necrosis). The upper right quadrant shows cells that
stained positive for both annexin V-FITC and PI, which indicates
cells in late apoptosis. The lower left quadrant shows cells that did
not stain for either annexin V-FITC or PI and thus represent viable
cells. The lower right quadrant shows cells that stained for annexin
V-FITC, representing cells in early apoptosis. We compared
annexin V staining for early apoptosis in FET-a and FET-a-DN
cells (Fig. 4B). Controls for this experiment were unstained cells
and cells stained with either annexin V-FITC or PI only. The
results show that 10-fold more FET-a cells stained positive
for annexin V-FITC compared with FET-a-DN cells after 48 h
of GFDS. Similar results were obtained from PARP (poly
[ADP-ribose] polymerase) cleavage as assessed by immunoblot
analysis.30
Increased Akt activation through repression of TGF-b
signalling contributes to cell survival
Based on the observation that TGF-b signalling can repress Akt
activation in these cells, we determined whether Akt activation
was responsible for the enhanced cell survival that resulted from
the loss of TGF-b inhibitory signalling in FET-a-DN cells. Cells
were grown to 80% confluence and pelleted or deprived of growth
factors for 48 h, after which immunoblot analysis to probe for Akt
phosphorylation with total Akt as a loading control was con-
ducted. The results showed that phosphorylation of Akt decreased
in FET-a cells during GFDS, whereas Akt phosphorylation was
persistent in FET-a-DN cells under the same conditions (Fig. 5A).
To confirm that Akt was linked to cell survival in FET-a-DN cells,
we used LY294002, a potent inhibitor of PI3K which is upstream
of the activation of Akt. To verify that LY294002 could inhibit Akt
activity, cells were grown to 80% confluence and then deprived of
growth factors in the presence of DMSO (the drug carrier) or
25 mM LY294002 for 48 h, after which immunoblot analysis for
phosphorylated Akt was performed. The results showed that
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Figure 4 Abrogation of TGF-b tumour suppressor signalling in vitro results in enhanced survival during growth factor deprivation stress
(GFDS). (A) Annexin V-FITC/PI staining of FET-a and FET-a-DN cells. (B) Comparison of apoptotic cell rates between FET-a and FET-a-DN
cells in response to GFDS
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LY294002 effectively inhibited phosphorylation of Akt and did
not change total Akt expression (Fig. 5B). The effect of LY294002
inhibition on cell survival was determined by growing cells to 80%
confluence and depriving them of growth factors for 48 h in the
presence of DMSO or 25 mM LY294002. Apoptosis was interro-
gated by annexin V-FITC/PI staining and DNA fragmentation.
The results from annexin V-FITC/PI staining showed that FET-
a-DN cells treated with LY294002 exhibited a two-fold increase in
positive staining for annexin V-FITC (Fig. 6).
Collectively, these data suggest that increased Akt activation
resulting from the abrogation of TGF-b tumour suppressor sig-
nalling contributes to enhanced cell survival, as reflected by the
lower apoptotic rates observed in TUNEL staining of FET-a-DN
tumours relative to FET-a tumours.
The results with the FET cell model indicate that TGF-b signal-
ling is a metastasis suppressor, as demonstrated by the acquisition
by FET-a of an invasive and highly metastatic capability following
the elimination of tumour suppressive TGF-b RII signalling. We
extended these results by using the reverse strategy to inhibit
metastatic capability in another native colon carcinoma cell line
(CBS4) by the genetic rescue of TGF-b Smad signalling through
transfection of TGF-b receptors in an additional human colon
cancer orthotopic model. CBS4 is a human colon carcinoma cell
line that has a compromised TGF-b signalling pathway as a result
of reduced expression of TGF-b receptor type II.24 TGF-b sensi-
tivity was restored to native CBS4 cells through the reintroduction
of TGF-b type II receptor (designated CBS4-RII). We noted 100%
invasiveness at the primary site in both CBS4 and CBS4-RII, but
the rate of metastasis decreased from 65% in CBS4 to 10% in
CBS4-RII. Taken together with the FET-a-DN studies, these
results introduce a novel role for TGF-b signalling as a metastasis
suppressor, in conjunction with that as a suppressor of tumour
initiation.
Discussion
Better understanding of the molecular changes that drive the
metastasis responsible for most cancer-related deaths is vital.
TGF-b tumour suppression involves cytostasis through the induc-
tion of cell cycle regulators, differentiation promotion, suppres-
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sion of tumorigenic inflammation and proapoptotic signalling.31
The specific mechanism by which TGF-b elicits a proapoptotic
effect in relation to the prevention of metastatic evolution is not
clear. The loss of TGF-b tumour suppressor activity influences
tumour promotion, resulting in the loss of cytostasis, acquisition
of tumorigenic properties including epithelial-mesenchymal tran-
sition (EMT), production of mitogens, evasion of immunity and
eventual metastasis.31 TGF-b has been shown to prime breast
cancer cells for metastasis to the lung through effects on the cells
in the lung microenvironment. Similarly, TGF-b interacts with the
bone microenvironment to enhance breast cancer metastasis.20,32
However, our results show a novel role for TGF-b signalling in
human colon carcinoma as a direct metastatic suppressor through
the regulation of cell survival in invasive, but not yet metastatic,
cells. TGF-b metastatic suppression occurs in FET human colon
cancer cells through the inhibition of cell survival signalling,
which is mediated by Akt and survivin.3
The metastatic process is complex and has multiple mechanisms
that must be acquired by tumour cells before they obtain a robust
metastatic capability. Two important rate-limiting steps to
metastasis are invasion and distal colony formation. There are
relatively few in vivo model systems that will facilitate the study of
invasion and distal colony formation as separate steps in the meta-
static cascade. We have utilized an orthotopic implantation model
of colon cancer to allow these events to be observed.The orthotopic
implantation model allows the progression of colon cancer evi-
denced by the invasion of the bowel wall and of distal colonization
to the liver and lungs to be assessed. These sites of metastasis
recapitulate the natural progression of human disease. Our results
show that both FET-a and FET-a-DN cells were able to invade the
bowel wall and the normal colon crypts to form a carcinoma.
However, the orthotopic implants showed that the FET-a-DN cells
with abrogated TGF-b signalling were able to effectively colonize
distant organs from the primary colonic site of the tumour, empha-
sizing the role of TGF-b as a metastasis suppressor. Maintenance of
the balance between oncogenes and tumour suppressor activities is
necessary to the normal functioning of cells and tissues; however,
when the balance shifts toward oncogenicity, tumorigenesis results.
The activation of oncogenes (i.e. EGFR) and/or the inactivation of
tumour suppressors (i.e. TGF-b) are involved in promoting cell
survival during tumorigenicity and metastasis. Tumorigenicity
results from the accumulation of many shifts in balance between
these types of activities. The ability of malignant cells to withstand
environmental stress is considered an important factor in tumour
development and progression.33 Tumour cells must overcome
many restrictions in order to survive, propagate and colonize distal
organ sites. The loss of apoptosis mediated by TGF-b appears to
contribute to tumour progression and metastasis under such stress
conditions. In this study, we have shown that abrogation of TGF-b
signalling enables increased Akt activation in FET-a-DN cells
under stress conditions such as GFDS, leading to a shift from
support of apoptosis to survival, thus contributing to resistance to
stress-induced apoptosis.
The dichotomous role of TGF-b signalling is problematic to
understanding the consequences of TGF-b signalling and how to
effectively target aberrant TGF-b signalling in cancer. Currently,
the development of TGF-b inhibitors in treating cancers has
increased as a result of growing clinical evidence that TGF-b acts
as a tumour-derived immunosuppressor, an inducer of mitogens
and a promoter of carcinoma invasion, and is able to trigger
prometastatic cytokine secretion.31 However, our results now
show that inhibition of TGF-b signalling can promote metastasis
in invasive cancer cells that have not yet progressed to metastatic
colonization. Therefore, inhibiting TGF-b signalling in primary
tumours may enhance the metastatic capability of the tumour
cells.
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